StockData

Bolt Biotherapeutics vs Ensysce Biosciences

BOLT and ENSC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BOLT and ENSC compare

Bolt Biotherapeutics is the larger company, worth 1.5 times as much as Ensysce Biosciences ($11.4M against $7.5M).

Ensysce Biosciences grew revenue faster over the last twelve months (37.9% versus 12.8% for Bolt Biotherapeutics).

Bolt Biotherapeutics scores higher on the StockData Score (11 against 9 for Ensysce Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBOLTENSC
Size and price
Market cap$11.4M$7.5M
Share price$5.91$0.387
Change, 1 year22.9%−81.0%
Change, 5 years−96.6%−100.0%
Beta (5Y)0.612.57
Employees238
StockData Score
Total score11 (better)9
Valuation score33
Growth score22
Performance score1 (better)0
Health score5 (better)4
Dividend score00
Valuation
P/S2.4×1.2× (better)
P/B0.9×0.3× (better)
Fair value$8.92$1.78
Margin of safety33.7%78.2% (better)
Growth
Revenue growth (TTM)12.8%37.9% (better)
Revenue growth, 5Y average102% (better)5.2%
Profitability
Operating margin−655% (better)−1477%
Net margin−611%–
Return on equity−112%–
Financial health
Debt / equity0.000.00
Interest coverage–−7157.6×
Current ratio2.618.02 (better)
Altman Z-score−18.28−17.64 (better)
Piotroski F-score5–
Dividends and buybacks
Buyback yield−0.26%–
Shareholder yield−0.26%0.00% (better)
Ownership
Held by institutions31.0%4.7%
Held by insiders12.2%6.2%
Insider net buying, 12 months$196K$444K (better)
Short interest, % of float2.8%0.49%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.